A Study For Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator

Inclusion Criteria:

• Diagnosed with Symptomatic paroxysmal atrial fibrillation (PAF) defined as as atrialfibrillation (AF) that terminates spontaneously or with intervention within 7 daysof onset. This PAF is considered to be symptomatic if symptoms related to AF areexperienced by the participant

• Selected for AF ablation procedure by pulmonary vein isolation (PVI)

• Willing and capable of providing consent

• Able and willing to comply with all pre-, post- and follow-up testing andrequirements

Exclusion Criteria:

• Previously known AF secondary to electrolyte imbalance, thyroid disease, orreversible or non-cardiac cause (example, documented obstructive sleep apnea, acutealcohol toxicity, morbid obesity [body mass index greater than {>} 40 kilograms permeter square {kg/m^2}]), renal insufficiency (with an estimated creatinine clearanceless than (<) 30 milliliters per minute per 1.73 meter square [mL/min/1.73 m^2])

• Previous left atrium (LA) ablation or surgery

• Participants known to require ablation outside the PV region (example,atrioventricular reentrant tachycardia, atrioventricular nodal re-entry tachycardia,atrial tachycardia, ventricular tachycardia and Wolff-Parkinson-White)

• Previously diagnosed with persistent AF (> 7 days in duration)

• Severe dilatation of the left atrium (LA) (left anterior descending artery [LAD] >50millimeter [mm] antero-posterior diameter in case of transthoracic echocardiography [TTE])

• Presence of LA thrombus

• Severely compromised left ventricular ejection fraction (left ventricular ejectionfraction [LVEF] <40 percentage [%])

• Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV

• History of blood clotting, bleeding abnormalities or contraindication toanticoagulation (heparin, warfarin, or dabigatran)

• History of a documented thromboembolic event (including transient ischemic attack [TIA]) within the past 6 months

• Previous percutaneous coronary intervention (PCI) / myocardial infarction (MI)within the past 2 months

• Previous coronary artery bypass grafting (CABG) in conjunction with valvularsurgery, cardiac surgery (example, ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure

• Unstable angina pectoris within the past 6 months

• Anticipated cardiac transplantation, cardiac surgery, or other major surgery withinthe next 12 months

• Significant pulmonary disease (example, restrictive pulmonary disease, constrictiveor chronic obstructive pulmonary disease) or any other disease or malfunction of thelungs or respiratory system that produces severe chronic symptoms

• Known significant pulmonary vein (PV) anomaly that in the opinion of theinvestigator would preclude enrollment in this study

• Prior diagnosis of pulmonary vein stenosis

• Pre-existing hemi diaphragmatic paralysis

• Acute illness, active systemic infection, or sepsis

• Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch orother abnormality that precludes catheter introduction or manipulation

• Severe mitral regurgitation

• Presence of implanted pacemaker or implantable cardioverter-defibrillator (ICD) orother implanted metal cardiac device that may interfere with the pulsed electricfield energy

• Presence of a condition that precludes vascular access (such as Inferior Vena Cava [IVC] filter)

• Significant congenital anomaly or a medical problem that in the opinion of theinvestigator would preclude enrollment in this study

• Categorized as vulnerable population and requires special treatment with respect tosafeguards of well-being

• Current enrollment in an investigational study evaluating another device or drug

• Women who are pregnant (as evidenced by pregnancy test if pre-menopausal),lactating, or who are of child-bearing age and plan on becoming pregnant during thecourse of the clinical investigation

• Life expectancy less than 12 months

• Presenting contra-indications for the devices used in the study, as indicated in therespective Instructions For Use (IFU)

• Known contraindication for magnetic resonance imaging (MRI) such as use of contrastagents due to advanced renal disease, claustrophobia etcetra. (at principleinvestigator [PI] discretion)

• Presence of iron-containing metal fragments in the body

• Known unresolved pre-existing neurological deficit

• Known uncontrolled significant gastroesophageal reflux disease (GERD)